Sacituzumab govitecan in Japanese participants with HR+/HER2− metastatic breast cancer: primary results from the phase II ASCENT-J02 study

Although the primary endpoint (ORR by IRC) was not met (P > .025), overall efficacy results were generally similar to TROPiCS-02, supporting access to SG in Japanese patients with HR+/HER2- mBC. Safety was consistent with the known and manageable SG safety profile.

Authors

Institutions

Publication Details

Journal
Japanese Journal of Clinical Oncology
Published
2026-03-27
DOI
https://doi.org/10.1093/jjco/hyag043
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Sacituzumab govitecan in Japanese participants with HR+/HER2− metastatic breast cancer: primary results from the phase II ASCENT-J02 study

Sunita Padman, Yuki Iwahori, Danh Huynh, Tsutomu Iwasa et al.
Japanese Journal of Clinical Oncology
HER2/EGFR in Cancer Research
article

Sacituzumab govitecan in Japanese participants with HR+/HER2− metastatic breast cancer: primary results from the phase II ASCENT-J02 study

Sunita Padman, Yuki Iwahori, Danh Huynh, Tsutomu Iwasa, J. Shao, Takahiro Kogawa, Tadahiko Shien, Kenta Watanabe, J. Kwan, Junichiro Watanabe, Koji Matsumoto, Takahiro Nakayama, Hiroji Iwata, Akihiko Shimomura, Yoichi Naito
article en

Abstract

Although the primary endpoint (ORR by IRC) was not met (P > .025), overall efficacy results were generally similar to TROPiCS-02, supporting access to SG in Japanese patients with HR+/HER2- mBC. Safety was consistent with the known and manageable SG safety profile.

Japanese Journal of Clinical Oncology
Tokyo Metropolitan Government (JP), Juntendo University (JP), Nagoya University Hospital (JP), National Center for Global Health and Medicine (JP), Okayama University Hospital (JP), Osaka International Cancer Institute (JP), Kindai University Sakai Hospital (JP), The Cancer Institute Hospital (JP), Gilead Sciences (United States) (US), National Cancer Center Hospital East (JP), Juntendo University Hospital (JP), Hyogo Prefectural Cancer Center (JP), Sapporo National Hospital (JP), Nagoya University (JP)
Good health and well-being
Openalex Percentile: Top 7%
HER2/EGFR in Cancer Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Sacituzumab govitecan in Japanese participants with HR+/HER2− metastatic breast cancer: primary results from the phase II ASCENT-J02 study — Sunita Padman, Yuki Iwahori, et al. · Japanese Journal of Clinical Oncology (2026) | TGRS Research Map | TGRS